newsfilter
← Latest News
GlobeNewswire·

Immutep Quarterly Activities Report Q3 FY25

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient